» Articles » PMID: 32067052

A Meta-analysis on Anticoagulation After Vascular Trauma

Overview
Date 2020 Feb 19
PMID 32067052
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: There is much debate regarding the use of anticoagulation following vascular trauma. The aim of this meta-analysis was to compare the outcome of trauma following administration of anticoagulation medication.

Methods: The literature search was carried out using Ovid MEDLINE and PubMed databases to search for keywords and MeSH terms including "Anticoagulation", "Vascular Surgery", "Vascular Trauma", "Vascular Repair", "Repair" and "Wounds and Injuries".

Results: Use of anticoagulation was associated with a better prognosis for overall vascular trauma outcomes (weighted OR 0.46; 95% CI 0.34-0.64; P < 0.00001), as well as reduced risk of amputation for both lower and upper limb vascular trauma (weighted OR 0.42; 95% CI 0.22-0.78; P = 0.007), and reduced occurrence of reoperation events and amputations in isolated lower limb vascular trauma (weighted OR 0.27; 95% CI 0.14-0.52; P < 0.0001).

Conclusion: There was a statistically significant correlation between the use of anticoagulation and vascular trauma outcome. A major limitation with many of the studies includes a lack of prospective analysis and therefore we recommend prospective studies to properly elucidate prognostic outcomes following use of these anticoagulants. Further studies need to be conducted to assess the effects of timing of anticoagulant delivery, dosages and severity of traumatic injury. Thus, this would prove to be very useful in the formation of guidelines.

Citing Articles

Heparin-Induced Thrombocytopenia After Revascularization of Gustilo-Anderson Type IIIC Open Lower Leg Fracture: A Case Report of Subsequent Ischemic Limb Salvage Failure.

Hatori Y, Tajika T, Kuboi T, Negishi R, Chikuda H Am J Case Rep. 2024; 25:e944121.

PMID: 38944681 PMC: 11332957. DOI: 10.12659/AJCR.944121.


Timing and choice of systemic anticoagulation in the setting of extremity arterial injury repair.

Argandykov D, Proano-Zamudio J, Dorken-Gallastegi A, Gebran A, Renne A, Paranjape C Eur J Trauma Emerg Surg. 2022; 49(1):473-485.

PMID: 36203031 DOI: 10.1007/s00068-022-02092-w.


[23/m-Psychosis with sequelae : Preparation for the medical specialist examination: part 46].

Helfen T Unfallchirurg. 2020; 124(Suppl 1):123-128.

PMID: 33216201 DOI: 10.1007/s00113-020-00918-z.

References
1.
Snyder 3rd W . Vascular injuries near the knee: an updated series and overview of the problem. Surgery. 1982; 91(5):502-6. View

2.
Patrono C, Baigent C, Hirsh J, Roth G . Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):199S-233S. DOI: 10.1378/chest.08-0672. View

3.
Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G . Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol. 2010; 150(3):325-31. DOI: 10.1016/j.ijcard.2010.08.035. View

4.
Diener H, Cunha L, Forbes C, Sivenius J, Smets P, LOWENTHAL A . European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996; 143(1-2):1-13. DOI: 10.1016/s0022-510x(96)00308-5. View

5.
Katakami N, Kim Y, Kawamori R, Yamasaki Y . The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation. 2010; 121(23):2584-91. DOI: 10.1161/CIRCULATIONAHA.109.892414. View